Patient Tolerability of Talquetamab and Use of IVIG
Panelists discuss how recent PET is reviewed with the patient, and there is evidence of near resolution of PET avid EMD lesions, though they will continue to monitor adenopathy – most suspicious for a reactive process. For patients treated with IVIG, the goal is to maintain a biological level of IgG at 400 mg/dL.
EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
EP: 2.Role of Step-Up Dosing
EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy
EP: 4.Strategies For Management of Infections
EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy
Now Viewing
EP: 7.Patient Tolerability of Talquetamab and Use of IVIG
EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
Video content above is prompted by the following:
- Please walk through the patient’s treatment course on talquetamab, including what issues you have seen and how they have been dealt with.
- How do physicians think differently about the use of IVIGs for patients treated with talquetamab?
Related Content
